Document Detail


Overview of present day treatment of Parkinson's disease.
MedLine Citation:
PMID:  745015     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the light of present day knowledge, augmenting striatal dopaminergic activity is the most effective means for controlling the symptoms of parkinsonism. This is best accomplished by the administration of levodopa with a peripheral decarboxylase inhibitor. However, limitations in its benefits develop after long-term administration in a substantial number of patients. In an attempt to overcome these a number of pharmacological agents acting on striatal dopaminergic mechanisms have undergone clinical trial. Of those tried Deprenyl, an MAO-B inhibitor, given with levodopa and carbidopa has shown the most promise. Preliminary results in 35 patients indicate that it is useful in diminishing the incidence of "on-off" phenomena--one of the most limiting reactions to levodopa--as well as enabling some patients to recoup their loss of therapeutic benefits. Though far from resolving all of the therapeutic difficulties encountered with prolonged use of levodopa, it appears to be a valuable adjunctive agent for the long-term problem patient.
Authors:
M D Yahr
Related Documents :
20668935 - Hypovitaminosis d and insulin resistance in peritoneal dialysis patients.
19224315 - Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systemat...
19783195 - Olfaction and apathy in parkinson's disease.
19131155 - The relation of testosterone levels with fatigue and apathy in parkinson's disease.
7994815 - Long-term results of dual-chamber (ddd) pacing in obstructive hypertrophic cardiomyopat...
8956575 - Meckel's enteroliths: clinical, radiologic, and pathologic findings.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of neural transmission     Volume:  43     ISSN:  0300-9564     ISO Abbreviation:  J. Neural Transm.     Publication Date:  1978  
Date Detail:
Created Date:  1979-05-23     Completed Date:  1979-05-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0337042     Medline TA:  J Neural Transm     Country:  AUSTRIA    
Other Details:
Languages:  eng     Pagination:  227-38     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Bromocriptine / pharmacology
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Humans
Levodopa / blood,  therapeutic use*
Male
Middle Aged
Parkinson Disease / drug therapy*
Phenethylamines / therapeutic use*
Receptors, Dopamine / drug effects
Selegiline / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Levodopa; 0/Phenethylamines; 0/Receptors, Dopamine; 14611-51-9/Selegiline; 25614-03-3/Bromocriptine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Absence of "cheese effect" during deprenyl therapy: some recent studies.
Next Document:  Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administratio...